Data investigation

How to Get a GLP-1 Covered by Insurance

Coverage is decided in three steps, and most people give up at the wrong one. An exclusion is not the same as a denial, and appealing is worth it for just one of the two.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
8 min read·7 citations

Coverage for GLP-1 weight-management drugs is decided in three steps, and most people give up at the wrong one. First, whether your plan covers this category at all. Second, whether you meet the criteria it applies. Third, whether a denial is worth appealing. Sometimes it is not, because an exclusion and a denial are different things and only one of them can be argued with.

This is the mechanism, in the order it runs, with the questions that get you a straight answer at each stage. It will not promise you approval, but it will tell you quickly whether you are in a fight worth having, so you are not spending six weeks on an appeal against a plan that never covered the category.

Step one: is the category covered at all?

Before anything else, find out whether your plan excludes weight-management drugs as a class, as North Carolina’s State Health Plan has since 2024. Many employer plans do, particularly self-funded ones, where the employer rather than the insurer decides what is covered and is paying the claims directly. The same employer choice decides whether a pharmacy benefit manager’s formulary change reaches you, as CVS Caremark’s Zepbound reversal shows. This is the single most important fact and the one most people discover last.

An exclusion is not a denial. A denial says you did not meet the criteria, and criteria can be argued. An exclusion says the benefit does not exist under your plan, and no clinical argument changes that, because the appeal has nothing to overturn. If the category is excluded, your realistic routes are a different indication (below), a manufacturer program, or paying cash. Knowing which situation you are in on day one is worth more than any letter.
On Medicare, the rules are different. Part D cannot cover drugs used for weight loss, but the temporary Medicare GLP-1 Bridge pays for Foundayo, Wegovy and the Zepbound KwikPen at a $50 monthly copay for people who meet its criteria, through December 31, 2027. Type 2 diabetes, moderate-to-severe sleep apnea and fatty liver disease are excluded, because Part D may already cover those.[7] Our Bridge guide walks through who qualifies.

Ask the member-services line one precise question: “Does my plan cover drugs for chronic weight management, and if so which ones are on formulary and at what tier?” Vague questions get vague answers. Ask for it in writing, and ask for the plan document language rather than a summary. For the largest carriers we summarize what each one publishes, such as UnitedHealthcare’s prior-authorization terms and Kaiser Permanente’s restricted formularies, which helps you know what to ask.

While you are on the phone, ask whether your employer or plan sponsors a weight program outside the drug benefit. FlyteHealth, for example, sells physician-led cardiometabolic care to employers, payers and health plans, prescribes a GLP-1 only when it fits, and says most of the medication it uses is not a GLP-1.

Step two: the criteria, and the diagnosis that changes them

Where the category is covered, it almost always sits behind prior authorization, meaning your prescriber has to justify the prescription before the plan will pay. The criteria vary by plan, but they are usually built from the same parts: a BMI threshold, sometimes a weight-related condition alongside it, sometimes documented prior attempts at weight loss, and sometimes a requirement to try a cheaper drug first. A prescriber who bills your plan does that paperwork for you; our board of GLP-1 providers that take insurance lists the online sellers whose own descriptions say they accept or coordinate it.

  • BMI threshold. Commonly 30, or 27 with a weight-related condition. That is the same structure the pivotal trials used for enrollment.
  • Documented prior attempts. Some plans want a record of supervised weight-management effort. If you have one, it belongs in the request; if you do not, ask what counts before assuming you fail.
  • Step therapy. Trying an older or cheaper drug first, usually Contrave or Qsymia. This is common and it is appealable when the required drug is contraindicated for you or has already failed.
  • Continuation criteria. Approval is often for a limited period with a weight-loss threshold to renew. Ask what that threshold is at the start rather than discovering it at month six.

The most consequential point in this step: a different indication is a different conversation. Obstructive sleep apnea, established cardiovascular disease and type 2 diabetes each have completed outcomes trials behind them, and plans treat them differently from weight alone. If you have one of these, or suspect you might (sleep apnea in particular is widely undiagnosed), raise it with your clinician before a weight-based request is filed. Our trial pages set out what each of those indications rests on.

Step three: if it is denied

  1. Get the reason in writing. A denial notice must state a reason. That reason determines everything that follows, and a phone summary of it is not good enough.
  2. Check whether it is an exclusion or a criteria failure. If the plan excludes the category, stop and change route. If you missed a criterion, find out precisely which one.
  3. Fix the specific gap. Missing documentation is the most common and most fixable reason: a prior attempt that was not recorded, a comorbidity not coded, a BMI from the wrong date.
  4. Ask for a peer-to-peer review. Your prescriber speaks to the plan’s reviewing clinician directly. It is often faster and more effective than a written appeal, and many prescribers will do it if asked.
  5. Escalate to external review if internal appeals fail. Most plans are subject to an independent external review, which is decided outside the insurer.[3] It is not a formality, and it is not universally available, so ask whether your plan is subject to it.
A letter is easier to send than to write. Our prior-authorization letter generator assembles a request from your details for your prescriber to review and sign, and the employer coverage checker and state Medicaid checker cover the two questions people most often get wrong about their own plan.

When cash beats the copay

Coverage is not automatically the cheaper route, and this is the arithmetic people skip. On a high-deductible plan you may pay the full brand price, frequently over $1,000 a month, until the deductible is met. Against that, when this guide was written in August 2026, compounded cash prices in this register ran from about $79 a month for semaglutide and $99 for tirzepatide, with medians near $190 and $264. The manufacturers now sell the approved drugs for cash too. The Wegovy pill starts at $149 a month and Foundayo at $149.[4][5] A Zepbound KwikPen runs $299 at the starting dose and $699 at the top three doses at the regular price.[6]

That is not an argument for skipping insurance; a met deductible and a $25 copay beats everything. It is an argument for doing the sum before you assume, and, for anyone uninsured on a low income, for checking the manufacturers’ free-medicine programs first. Our guide to the cash market sets out what the compounded route involves, including what you give up.

If you end up paying cash, pre-tax money may still apply. Woodwork, Harbor and LifeVine Wellness list HSA/FSA eligibility, and so do Rila and AVArx. FormidableMD, which bills per visit in four states, and Blis MD, which sells one month at a time, list it as well. TrimRx takes eligible HSA and FSA cards and also offers installment plans through Affirm, Klarna and Afterpay. Our ranking of HSA and FSA semaglutide sellers covers sellers that name those accounts in their published terms. Your account administrator has the final word on what it will reimburse.

Check what an eligible charge pays for, too. Genesis Health lists FSA/HSA eligibility, and its plans fold the doctor visit and coaching into the monthly price instead of billing them separately. Collective is also advertised as HSA/FSA eligible, but its $59 monthly price for compounded semaglutide leaves out the $199 annual membership it requires.

Insurance can also cover the visit when the drug is a separate question. Doctronic charges your copay, or $39 without insurance, for a video visit, and its doctors send a Wegovy or Zepbound prescription to your own pharmacy, where your plan’s coverage sets what the medication costs.

Common questions

Frequently Asked Questions

Confirm first that your plan covers weight-management drugs at all, since many employer plans exclude the category. If it does, expect prior authorization: your prescriber submits clinical justification, typically against a BMI threshold with or without a weight-related condition, and sometimes a step-therapy requirement. Ask member services for the criteria in writing before the request is filed rather than after it is denied.
A denial means you did not meet the plan's criteria, and criteria can be appealed. An exclusion means the benefit does not exist under your plan at all, and an appeal has nothing to overturn. This distinction decides whether an appeal is worth your time, and it is the first thing to establish.
It can change the question entirely. Zepbound carries an FDA indication for obstructive sleep apnea and Wegovy one for cardiovascular risk reduction, both backed by completed outcomes trials. A plan that excludes weight-management drugs may still cover a drug prescribed for one of those. It is worth raising with your clinician before a weight-based request goes in.
For commercial and marketplace plans, federal rules give the insurer up to 15 days to decide a prior authorization, or 72 hours when care is urgent. When you ask about turnaround, ask for the appeal deadline too. Appeal windows are finite, and they are the thing people most often miss.
Often yes. Step therapy is generally appealable where the required drug is contraindicated for you, has already failed, or is expected to be ineffective given your history. That is a clinical argument your prescriber makes, and it is one of the more winnable appeals.
Usually not. The Wegovy and Zepbound savings cards require commercial insurance and exclude anyone on Medicare, Medicaid, VA or TRICARE. What exists for cash payers is the manufacturers' own direct programs, plus the compounded market this register tracks. As of October 2026 the direct prices run from $149 a month for the starting doses of the Wegovy pill and Foundayo to $699 for the highest Zepbound KwikPen doses at the regular price.

References

  1. 1.U.S. National Library of Medicine WEGOVY (semaglutide) injection — prescribing information, including approved indications DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
  2. 2.U.S. National Library of Medicine ZEPBOUND (tirzepatide) injection — prescribing information, including the obstructive sleep apnea indication DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
  3. 3.Centers for Medicare & Medicaid Services Appeals in a health plan — internal appeals and external review HealthCare.gov. 2026. https://www.healthcare.gov/appeal-insurance-company-decision/appeals/
  4. 4.Novo Nordisk Wegovy savings offer — self-pay prices for Wegovy pill and Wegovy injection NovoCare. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html
  5. 5.Eli Lilly and Company Foundayo (orforglipron) — LillyDirect self-pay prices by dose LillyDirect. 2026. https://www.lilly.com/lillydirect/foundayo
  6. 6.Eli Lilly and Company Zepbound savings and self-pay — regular price for a 1-month supply of Zepbound single-patient-use KwikPen Lilly. 2026. https://zepbound.lilly.com/savings
  7. 7.Centers for Medicare & Medicaid Services Weight loss drugs — Medicare GLP-1 Bridge coverage, eligibility, covered drugs and costs Medicare.gov. 2026. https://www.medicare.gov/coverage/weight-loss-drugs

Buying a GLP-1 With No Insurance: What It Really Costs

Compounded semaglutide runs $79 to $299 a month across 556 sellers; tirzepatide $99 to $399. The spread is four to one for the same molecule. This explains what decides where you land.

8 min read

CVS Caremark and Zepbound: Coverage Is Back, but Check Your Plan

CVS Caremark put Zepbound back on its main commercial formularies as a preferred drug on October 1, 2026, after dropping it for Wegovy in July 2025. Employers can still exclude it. How to check your plan, request an exception, pay cash, or switch.

10 min read

Is Zepbound a Semaglutide? Brand Names vs Molecules

No. Zepbound is tirzepatide, the same molecule as Mounjaro. Nine brand names cover five molecules, and knowing which is which decides your price and your coverage.

6 min read

TRICARE, FEHB and PSHB: Who Covers Wegovy and Zepbound in 2026

TRICARE's weight coverage for Wegovy, Zepbound and Saxenda applies only on Prime, Select and the premium plans, with prior authorization; TRICARE For Life is barred by law. OPM requires every FEHB and PSHB plan to cover a GLP-1, but each plan sets its criteria and tier.

9 min read

TrumpRx GLP-1 Prices: What Wegovy, Ozempic, Zepbound and Foundayo Cost

TrumpRx lists the Wegovy pill from $149, Wegovy and Ozempic pens at $199 then $349, Zepbound $299 to $449 and Foundayo $149 to $299. Every figure matches the manufacturer's own self-pay price. Who can use it, insurance, and when Medicare's $50 Bridge is cheaper.

11 min read

Mounjaro Alternatives: What Costs Less and What You Give Up

Zepbound is the same drug as Mounjaro and costs $299 to $449 a month self-pay against $499. Ozempic, Trulicity, oral semaglutide and generic liraglutide cost less but did less in head-to-head trials. Compounded tirzepatide, SGLT2s and metformin.

11 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

8.2

bmiMD

Starting below a standard dose, with microdose tiers

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →